OMEPRAZOLE Capsule

ក្រុមហ៊ុនផលិតឱសថ:

 

Berlin Pharmaceutical Industry Co., Ltd., Thailand

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    Omeprazole is a proton pump inhibitor indicated for:

    - Treatment in adults of duodenal and gastric ulcer

    - Treatment in adults and children of gastroesophageal reflux disease (GERD) and maintenance of healing of erosive esophagitis

    - Helicobacter Pylori eradication in peptic ulcer disease

    - Zollinger-Ellison syndrome

     

    Dosage and Administration

    These capsules should be taken before eating and should be swallowed whole. Antacids may concomitantly be used.

     

    Short term treatment of active duodenal ulcer

    20mg once daily.

    Most patients heal within 4 weeks. Some patients may require an additional 4 weeks of therapy.

     

    Gastric Ulcer

    40mg once daily for 4-8 weeks.

     

    Gastroesophageal Reflux Disease (GERD)

    No esophageal lesions: 20mg daily for up to 4 weeks.

    With erosive esophagitis and accompanying symptoms due to GERD is 20mg daily for 4-8 weeks.

     

    H.pylori Eradication for the Reduction of the Risk of Duodenal Ulcer Recurrence

    Triple therapy (Omeprazole/clarithromycin/amoxicillin) - omeprazole 20mg + clarithromycin50mg + amoxicillin 1000mg each given trice daily for 10 days.

    In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of omeprazole 20mg once daily is recommended for ulcer healing and symptom relief.

     

    Pathological Hypersecretory Conditions

    The dosage varies with the individual patient.

    The recommended adult oral starting dose is 60mg once daily.

    Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated.

    Doses up to 120 mg 3 times daily have been administered.

    Daily dosage of greater than 80mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with omeprazole for more than 5 years.

  • ហាមប្រើ

    In patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation.

    Hypersensitivity reactions include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis and urticaria.

  • ផលរំខាន

    Adults: Most common adverse reactions in adults are headache, abdominal pain, nausea, diarrhoea, vomiting, and flatulence

    Pediatric patients (1-6 years of age): Safety profile similar to that in adults, except that respiratory system events and fever were the most frequent reported reactions in pediatric studies.

  • អន្តរប្រតិកម្ម

    See the package insert about the details below:

    - atazanavir and nelfinavir

    - saquinavir

    - drugs for which gastric pH affects bioavailability (e.g. ketoconazole, iron salts, erlotinib, ampicillin esters, and digoxin)

    - clopidogrel

    - cilostazol

    - drugs metabolized by CYP450 (e.g. diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines)

    - warfarin

    - inhibitor of CYP2C19 and 3A4 (e.g. voriconazole)

    - tacrolimus

    - methotrexate

  • ការប្រុងប្រយ័ត្នជាពិសេស

    - Symptomatic response does not preclude the presence of gastric malignancy

    - Atrophic gastritis has been noted with long-term therapy

    - PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhoea

    - Avoid concomitant t use of omeprazole with clopidogrel

    - Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine

    - Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.

    - Avoid concomitant use of Miracid with St. John’s Wort of Rifampin due to the potential reduction in omeprazole concentrations.

    - Increase in intragastric pH may result in hypergastrinemia and increased Chromogranin

    A levels which may interfere with diagnostic investigations for neuroendocrine tumors.

  • សកម្មភាពឱសថ

    Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric mucosa for a day or more.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp